作者: Melissa Tan , Gerhardt Attard , Robert Huddart
DOI: 10.3390/IJMS19092568
关键词:
摘要: Circulating tumour DNA (ctDNA) is an attractive tool in cancer research, offering many advantages over tissue samples obtained using traditional biopsy methods. There has been increasing interest its application to muscle-invasive bladder (MIBC), which recognised be a heterogeneous disease with overall poor prognosis. Using range of platforms, studies have shown that ctDNA detectable MIBC and may useful biomarker monitoring status guiding treatment decisions patients. Currently, no such predictive or prognostic biomarkers clinical practice guide strategy, there real unmet need for personalised medicine approach MIBC, offers exciting avenue through pursue this goal. In article, we present overview work date on discuss the inherent challenges as well potential future applications.